儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估

doi:10.6040/j.issn.1673-3770.0.2021.117

摘要/Abstract

摘要： 目的评估尘螨过敏的过敏性鼻炎患儿进行舌下免疫治疗的短期疗效。方法回顾性分析2019年至2020年就诊于首都儿科研究所附属儿童医院耳鼻咽喉头颈外科,应用粉尘螨舌下特异性免疫治疗满6个月的患儿,分析其治疗前后的视觉模拟量表评分(VAS)、鼻部总症状评分(TNSS)、总用药评分(TMS)、症状药物联合评分(CSMS)。结果共纳入50例过敏性鼻炎患儿,平均(7.7±2.7)岁。治疗前VAS、TNSS、TMS、CSMS评分分别为(5.5±1.6)分、(5.5±2.2)分、(3.0±0.1)分、(4.3±0.6)分,治疗后6个月上述评分分别为(2.5±1.4)分、(2.2±1.6)分、(0.6±1.1)分、(1.2±1.2)分,治疗后较治疗前各评分均有下降(P<0.05)。结论粉尘螨舌下免疫治疗对于尘螨过敏性鼻炎的患儿短期疗效较好。

关键词: 过敏性鼻炎, 尘螨, 舌下免疫治疗

Abstract: Objective To evaluate the short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis. Methods Children attended in the department of otorhinolaryngology head and neck surgery, Capital Institute of Pediatrics affiliated Children's Hospital and received Dermatophagoides farinae specific sublingual immunotherapy for 6 months were enrolled from 2019 to 2020. Visual analogue scale(VAS), total nasal symptoms score(TNSS), total medication score(TMS), and combined symptom and medication score(CSMS)before and after immunotherapy were collected. Results In total 50 children with allergic rhinitis were enrolled, with an average age of(7.7±2.7)years old. Before immunotherapy, VAS, TNSS, TMS and CSMS was(5.5±1.6)score,(5.5±2.2)score,(3.0±0.1)score,(4.3±0.6)score, respectively. And after immunotherapy for 6 months, VAS, TNSS, TMS and CSMS was(2.5±1.4)score,(2.2±1.6)score,(0.6±1.1)score,(1.2±1.2)score, respectively. The scores were all decreased significantly after immunotherapy(P<0.05). Conclusion Short term efficacy of Dermatophagoides farinae specific sublingual immunotherapy is good for children with allergic rhinitis.

Key words: Allergic rhinitis, Dermatophagoides farinae, Sublingual immunotherapy

中图分类号:

R765

庞冲,边赛男,张冰,尹旭,陆颖霞,叶鹏飞,王湛,赵晶,高彦,关凯. 儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 70-74.

PANG Chong, BIAN Sainan, ZHANG Bing, YIN Xu, LU Yingxia, YE Pengfei, WANG Zhan, ZHAO Jing, GAO Yan, GUAN Kai. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74.

参考文献

[1] Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. Lancet[J] , 2011,378(9809):2112-2122. doi: 10.1016/S0140-6736(11)60130-X.
[2] Schuler Iv CF, Montejo JM. Allergic rhinitis in children and adolescents[J]. Pediatr Clin N Am, 2019, 66(5): 981-993. doi:10.1016/j.pcl.2019.06.004.
[3] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(1 Suppl): S1-S43. doi:10.1177/0194599814561600.
[4] Pfaar O, Agache I, de Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond[J]. Allergy, 2019, 74(Suppl 108): 3-25. doi:10.1111/all.14077.
[5] Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis[J]. Allergy, 2018, 73(4): 765-798. doi:10.1111/all.13317.
[6] Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy[J]. J Allergy Clin Immunol, 2015, 136(3): 556-568. doi:10.1016/j.jaci.2015.04.047.
[7] Wheatley LM, Togias A. Clinical practice. Allergic rhinitis[J]. N Engl J Med, 2015, 372(5): 456-463. doi: 10.1056/NEJMcp1412282.
[8] Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy[J]. Pediatr Allergy Immunol, 2017, 28(8): 728-745. doi:10.1111/pai.12807.
[9] Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? [J]. J Allergy Clin Immunol, 2016, 137(2): 339-349.e10. doi:10.1016/j.jaci.2015.12.1298.
[10] Vita D, Caminiti L, Ruggeri P, et al. Sublingual immunotherapy: adherence based on timing and monitoring control visits[J]. Allergy, 2010, 65(5): 668-669. doi:10.1111/j.1398-9995.2009.02223.x.
[11] Vogelberg C, Brüggenjürgen B, Richter H, et al. Real-world adherence and evidence of subcutaneous and sublingual immunotherapy in grass and tree pollen-induced allergic rhinitis and asthma[J]. Patient Prefer Adherence, 2020, 14: 817-827. doi:10.2147/PPA.S242957.
[12] Manzotti G, Riario-Sforza GG, Dimatteo M, et al. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment[J]. Eur Ann Allergy Clin Immunol, 2016, 48(6): 224-227.
[13] 刘湘, 楼响瑜, 高月秋, 等. 变应性鼻炎患者变应原谱及舌下免疫治疗分析[J]. 中国耳鼻咽喉头颈外科, 2019, 26(9): 491-494. doi:10.16066/j.1672-7002.2019.09.007. LIU Xiang, LOU Xiangyu, GAO Yueqiu, et al. Allergen spectrum and sublingual specific immunotherapy analysis in allergic thinitis patients[J]. Chinese Archives of Otolaryngology-Head and Neck Surgery, 2019, 26(9): 491-494. doi:10.16066/j.1672-7002.2019.09.007.
[14] Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis[J]. Cochrane Database Syst Rev, 2003(2): CD002893. doi:10.1002/14651858.cd002893.
[15] Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2016, 138(6): 1631-1638. doi:10.1016/j.jaci.2016.06.044.
[16] Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial[J]. J Allergy Clin Immunol, 2016, 137(2): 444-451.e8. doi:10.1016/j.jaci.2015.06.036.
[17] Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis[J]. J Allergy Clin Immunol, 2017, 139(6): 1840-1848.e10. doi:10.1016/j.jaci.2016.09.043.
[18] Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis[J]. Allergy, 2017, 72(11): 1597-1631. doi:10.1111/all.13201.
[19] Hoseini RF, Jabbari F, Rezaee A, et al. House dust mite sublingual-swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled Iranian study[J]. J Biol Regul Homeost Agents, 2018, 32(1): 83-88.
[20] 王丰, 张虹婷, 孟娟. 皮下免疫与舌下免疫治疗变应性鼻炎的疗效比较[J]. 重庆医学, 2017, 46(21): 2906-2908. doi:10.3969/j.issn.1671-8348.2017.21.008. WANG Feng, ZHANG Hongting, MENG Juan. Comparison of efficacy of subcutaneous immunotherapy and sublingual immunotherapy for treating allergic rhinitis[J]. Chongqing Medicine, 2017, 46(21): 2906-2908. doi:10.3969/j.issn.1671-8348.2017.21.008.
[21] Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis[J]. J Allergy Clin Immunol, 2014, 133(6): 1608-1614.e6. doi:10.1016/j.jaci.2013.11.012.
[22] Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet(ALK)improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms[J]. Ann Allergy Asthma Immunol, 2015, 114(2): 134-140. doi:10.1016/j.anai.2014.11.015.
[23] Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update[J]. World Allergy Organ J, 2014, 7(1): 6. doi:10.1186/1939-4551-7-6.
[24] Calderon MA, Casale TB, Nelson HS, et al. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies[J]. J Allergy Clin Immunol, 2013, 132(6): 1322-1336. doi:10.1016/j.jaci.2013.09.004.
[25] de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care[J]. Pediatr Allergy Immunol, 2012, 23(2): 150-158. doi:10.1111/j.1399-3038.2011.01219.x.

相关文章 15

[1]	杜康丽,郑振宇,徐战将,张宇,陈露,卢梦垚. 鼻中隔偏曲并发慢性鼻窦炎风险预测模型的构建与验证[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 78-86.
[2]	黄焕,华红利,邓玉琴,江承洋,王雨薇,杨星海. 儿童过敏性鼻炎、扁桃体腺样体肥大和鼻窦炎之间相关性及其对临床指导价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 34-41.
[3]	杨贵,胡田勇,贺海鹏,马莉,魏海峰,黄佳敏,刘志强. Der p2 B细胞表位RNA疫苗制备及其对过敏性鼻炎小鼠特异性IgE抑制作用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 6-12.
[4]	张杰,陈敏,申征征,吴宇华,刘原虎,孙浩,谭新华,倪树仁,杨书勋,史雪峥,倪鑫. 过敏性鼻炎与儿童新冠病毒肺炎感染及症状的关联性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 36-42.
[5]	张丽净,冯晓星,刘南仙,赵辉明,陈月华. 石墨烯养护鼻罩结合尘螨的皮下特异性免疫治疗在尘螨变应性鼻炎患者中的应用分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 26-32.
[6]	张真,杨卓莹,周佳妮,张大为,陈仁杰. 环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 13-20.
[7]	乌日柴夫,苏日古格,孟永梅. 卵清蛋白诱导的过敏性鼻炎豚鼠模型的建立与评价及蒙医舌尿诊的初步分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 32-38.
[8]	王剑,杜伟嘉,薛涛,陈福权. 利用百度指数分析中国过敏性鼻炎及相关变应性疾病的流行特征[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 31-41.
[9]	王晓嫒,张欠欠,程翔宇,李志鹏,张维天,叶海波. 翼管神经切断术治疗2型慢性鼻窦炎伴过敏性鼻炎的临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 42-49.
[10]	毕晓云,马本绪,王心茹,李旭豪,杨继国. 穴位贴敷治疗小儿过敏性鼻炎随机对照试验的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 75-85.
[11]	王惟一,时蕾,张志玉,张贵玲,时光刚. 高脂饮食对过敏性鼻炎小鼠致敏影响和肠道菌群改变的研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 21-29.
[12]	张雅琪,刘慧敏,曹淋曼,王子钰,林旭,李燕萍,薛刚,吴靖芳. MAPK、PI3K-AKT、NF-κB在小鼠过敏性鼻炎中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 254-259.
[13]	李孟辉,郅莉莉,戚凯文,王珊珊,高倩,步美玲,姜荷云,冯绛楠,王金荣. 皮下免疫治疗对单一尘螨和合并霉菌过敏儿童哮喘的临床研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 75-80.
[14]	王鑫,刘巧平,闫占峰,刘思溟,朱雅静,丁倩,张莹,田媛,张京然. 基于网络药理学探究小青龙汤治疗过敏性鼻炎的作用机制[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 46-55.
[15]	王宇婷，王嘉玺. microRNA在过敏性鼻炎发病机制中的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 98-104.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed